US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist

0.620
-0.034-5.26%

Close Jan 8 16:00 ET

0.629
+0.009+1.39%

Post 18:10 ET

158.62MMarket Cap-3.71P/E (TTM)

Adaptimmune Therapeutics Stock Forum

101674396

Dec 31, 2024 07:39

$Adaptimmune Therapeutics (ADAP.US)$ .. Only green for pre- market !!!

Jaguar8

Dec 2, 2024 18:05

🔴WATCHLIST Tuesday 12/3. NFA. Don’t open position without momentum. Use charts+indicators+order book. NO FOMO.

Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning.
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...

Trytosaveabit

Dec 2, 2024 15:03

Update

$Adaptimmune Therapeutics (ADAP.US)$ First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma

Trytosaveabit

Nov 13, 2024 16:14

Not to shabby!

$Adaptimmune Therapeutics (ADAP.US)$ Plus DATA to be presented for IGNYTE-ESO Trial of LETE-CEL in patients with SYNOVIAL SARCOMA! on 11/16/24 Saturday at CTOS annual meeting! ((((. Financial Results for the three and nine months ended September 30, 2024
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...

Stock_Drift

Nov 13, 2024 08:09

$Adaptimmune Therapeutics (ADAP.US)$

101674396

Oct 31, 2024 03:35

$Adaptimmune Therapeutics (ADAP.US)$ .. green when is the pre-market , will drop once open market!!!

Trytosaveabit

Sep 23, 2024 17:44

Newly filed 8K

$Adaptimmune Therapeutics (ADAP.US)$ Item 1.01Entry into a Material Definitive Agreement.
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8,...

Tonyco

Sep 8, 2024 17:22

$Adaptimmune Therapeutics (ADAP.US)$
so the spike in cash is from financing, fyi

Joy Boy or Bringer

Aug 29, 2024 12:36

50% at least please

20% before didn't TP. will wait patiently... or maybe CL...
after the product is approved, profitable, it's your time to shine.
$Adaptimmune Therapeutics (ADAP.US)$

Joy Boy or Bringer

Aug 29, 2024 08:43

different respond

hhh not happening for $Adaptimmune Therapeutics (ADAP.US)$
come on

BioCardia Says FDA Has Cleared Company To Market Its Morph DNA Steerable Introducer Product Family, Subject To The General Controls Provisions Of The Federal Food, Drug And Cosmetic Act - Filing

No comment yet

Heat List

Overall

No Data

Investment Theme

CAR-T Therapy

Intraday-0.95%